Exenatide Extended-Release: An Updated Review of Its Use in XXXX .

@entity1 @entity1697 @entity6 @entity12098 @entity344 @entity12350 @entity8142 @entity10 @entity42652 @entity2449
Exenatide extended-release (exenatide ER) [ @entity42652 (  )] is a @entity8142 agonist, approved for the treatment of @entity6 . It is injected subcutaneously by @entity1 once weekly, with no dose titration required. This article updates an earlier review of exenatide ER in the management of type 2 @entity6 , focusing on recently published data. In randomized, controlled trials, adjunctive exenatide ER 2 mg once weekly for 24-30 weeks significantly improved glycaemic control and reduced bodyweight in @entity1 with inadequately controlled type 2 @entity6 despite diet plus exercise and/or @entity1697 ( @entity1697 ). These beneficial effects of exenatide ER were maintained after up to 6 years of treatment. In @entity1 receiving one or more @entity1697 , addition of exenatide ER provided better glycaemic control than an immediate-release formulation of exenatide (exenatide twice daily), @entity12350 , @entity12098 , insulin glargine or insulin detemir, and was slightly less effective than liraglutide. In @entity1 treated with diet plus exercise alone, adjunctive exenatide ER was noninferior to @entity2449 and superior to @entity12350 , but was not noninferior to @entity12098 . Exenatide ER was generally well tolerated, with a low inherent risk of hypoglycaemia. The most common adverse events were mild to moderate @entity344 , injection-site reactions and @entity10 . Thus, exenatide ER is a useful treatment option in the management of type 2 @entity6 . It offers a convenient, once-weekly regimen and can be administered by @entity1 via a pen injection system or syringes and needles.
